哈尔滨三联药业股份有限公司 2021 年半年度报告全文 2021 年半年度报告 哈尔滨三联药业股份有限公司 2021-069 2021 年 08 月 1 哈尔滨三联药业股份有限公司 2021 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人秦剑飞、主管会计工作负责人赵志成及会计机构负责人(会计主 管人员)翟明卉声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司可能面临行业政策风险、新药研发风险、原材料价格波动及供应中断 风险、募投项目不达预期的风险、风险投资收益波动的风险等，详细内容已在 本报告第三节"管理层讨论与分析（十）、公司面临的风险和应对措施"部分予 以描述。敬请广大投资者注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 | 重要提示、目录和释义 | | 2 | | --- | --- | --- | --- | | 第二节 | 公司简介和主要财务指标 ...

Financial Performance - The company's operating revenue for Q1 2021 was ¥230,179,061.88, a decrease of 20.30% compared to ¥288,795,847.25 in the same period last year[8] - Net profit attributable to shareholders was ¥563,299,946.56, representing a significant increase of 1,660.87% from ¥31,989,844.02 year-on-year[8] - The net profit after deducting non-recurring gains and losses was -¥13,367,118.30, a decrease of 1,957.41% compared to ¥719,665.24 in the previous year[8] - The basic earnings per share rose to ¥1.78, up 1,680.00% from ¥0.10 in the same period last year[8] - The company reported a significant increase in undistributed profits, rising to CNY 876,849,656.40 from CNY 341,231,297.92, an increase of approximately 157%[39] - The company expects a significant increase in net profit for the year, projecting a net profit of CNY 55,000 million, which is a 1,856.54% increase compared to the previous year[27] - Basic earnings per share are projected to be CNY 1.74, reflecting an increase of 1,859.68% compared to the previous year[27] Assets and Liabilities - The total assets at the end of the reporting period were ¥3,029,396,416.51, an increase of 22.02% from ¥2,482,760,796.58 at the end of the previous year[8] - The total owner's equity increased to CNY 2,354,821,384.90 from CNY 1,791,577,744.66, marking an increase of about 31.4%[39] - Total liabilities decreased to CNY 674,575,031.61 from CNY 691,183,051.92, a reduction of approximately 2.4%[38] - The total assets reached CNY 3,129,172,534.87, compared to CNY 2,582,157,257.32 in the previous period, reflecting growth in the company's asset base[45] - Total liabilities decreased to CNY 561,592,080.70 from CNY 586,699,473.07 in the previous period[45] Cash Flow - The net cash flow from operating activities was -¥53,689,535.89, an improvement of 23.24% compared to -¥69,947,180.42 in the previous year[8] - The cash flow from operating activities showed a net outflow of CNY -53,689,535.89, an improvement from CNY -69,947,180.42 in the same period last year[54] - The cash inflow from investment activities was 20,183,375.58 CNY, compared to 367,625,156.95 CNY in the previous year, indicating a decrease in investment activity[58] - The net cash flow from investment activities was -336,969,016.27 CNY, indicating a significant outflow compared to the previous year's outflow of -8,908,778.33 CNY[58] - The cash flow from financing activities showed a net inflow of CNY 56,701,847.86, compared to CNY 9,814,639.46 in the previous year, reflecting a positive trend[55] Investments - The company reported non-recurring gains of ¥576,667,064.86, primarily due to the investment in 100% equity of Harbin Beixing Pharmaceutical Co., Ltd.[9] - Investment income surged by 8582.81% to ¥568,753,081.17, resulting from a 100% equity investment in Harbin Beixing Pharmaceutical Co., Ltd.[17] - The company made an investment in Harbin Fuyijia Technology Co., Ltd., acquiring 5% equity, resulting in an investment income of ¥56,649,000[19] - The company has committed a total investment of CNY 90,011.90 million for various projects, with a cumulative investment of CNY 28,980.84 million, representing 32.2% of the total commitment[24] Operational Changes - The marketing strategy is being adjusted to enhance the sales service system and improve market control capabilities[25] - The company adjusted its financial statements in accordance with the new leasing standards effective from January 1, 2021[63] - The company reported a long-term receivable of CNY 205,234,963.50, unchanged from the previous period[65] Shareholder Information - The total number of shareholders at the end of the reporting period was 37,766, with the top shareholder holding 39.07% of the shares[12]

Financial Performance - The company's operating revenue for 2020 was ¥1,338,882,990.74, a decrease of 36.31% compared to ¥2,102,061,189.57 in 2019[19]. - The net profit attributable to shareholders for 2020 was ¥29,324,801.54, down 83.45% from ¥177,184,368.25 in 2019[19]. - The net profit after deducting non-recurring gains and losses was -¥21,156,331.68 in 2020, a decline of 117.85% compared to ¥118,531,558.40 in 2019[19]. - The net cash flow from operating activities was -¥4,507,046.05 in 2020, a decrease of 101.41% from ¥320,140,786.74 in 2019[19]. - The basic and diluted earnings per share for 2020 were both ¥0.09, down 84.21% from ¥0.57 in 2019[19]. - The total assets at the end of 2020 were ¥2,482,760,796.58, a decrease of 7.09% from ¥2,672,123,690.27 at the end of 2019[19]. - The net assets attributable to shareholders at the end of 2020 were ¥1,775,280,766.14, down 3.13% from ¥1,832,695,727.36 at the end of 2019[19]. - The company reported a quarterly operating revenue of ¥372,419,584.32 in Q4 2020, with a net profit of ¥7,164,755.28[23]. - The company received government subsidies amounting to ¥82,859,947.05 in 2020, an increase compared to ¥38,683,531.09 in 2019[24]. - The total non-recurring gains and losses for 2020 amounted to ¥50,481,133.22, compared to ¥58,652,809.85 in 2019[24]. Shareholder Information - The company reported a total share capital of 316,600,050 shares as of December 31, 2020, with a cash dividend of 0.8 RMB per 10 shares to all shareholders[5]. - The company has a total of 309,784,867 shares available for dividend distribution after accounting for repurchased shares[5]. - The proposed cash dividend for 2020 is 0.8 yuan per share, totaling approximately 24.78 million yuan, pending shareholder approval[111]. - The cash dividend in 2020 represented 84.51% of the net profit attributable to ordinary shareholders[113]. - The total distributable profit for 2020 was reported at 341,231,297.92 CNY[114]. - The company has committed to maintaining a minimum cash dividend ratio of 20% during significant capital expenditure phases[114]. - The company’s cash dividend distribution strategy reflects a focus on returning value to shareholders while managing capital expenditures[114]. Risks and Challenges - The company faces risks including industry policy changes, new drug development risks, and fluctuations in raw material prices[5]. - The COVID-19 pandemic and the implementation of key monitored drug policies significantly impacted the company's main business operations[28]. - New drug development poses risks due to high costs and long cycles, necessitating careful project selection and management[102]. - The pharmaceutical industry is transitioning from rapid growth to high-quality development, facing challenges such as price reductions and increased market concentration[93]. Research and Development - R&D investment for the year was 112.0192 million yuan, accounting for 8.37% of the company's operating income[41]. - The company has a total of 295 R&D personnel, accounting for approximately 17.61% of the total workforce[35]. - The company is focusing on developing new products such as freeze-dried oral disintegrating tablets and new transdermal patches[65]. - The company activated 4 dormant products and successfully expanded its product lineup[42]. Corporate Governance and Compliance - The company emphasizes the importance of accurate financial reporting and has declared that its financial statements are true, accurate, and complete[4]. - The company has established a modern corporate governance structure, including a board of directors and various specialized committees[157]. - The company has implemented measures to stabilize stock prices, including withholding compensation for non-compliant executives for 10 trading days following a failure to act[117]. - The company has a long-term commitment to comply with all regulations and commitments made during the IPO process[116]. Social Responsibility and Environmental Initiatives - The company has invested over ¥10 million in environmental protection since its establishment, with an investment of over ¥350,000 in 2020[169]. - During the COVID-19 pandemic, the company donated nearly ¥1.5 million in cash and medicines to support the fight against the virus in Wuhan, including over 270,000 vials of medication[175]. - The company has implemented measures to comply with national air pollution control policies, including the removal of two coal-fired boilers and the installation of a gas boiler[184]. - The company has established a recyclable waste storage area for materials such as cardboard and plastic[185]. Market Position and Strategy - The company has a diverse product pipeline and a nationwide sales network, enhancing its competitive position in the pharmaceutical industry[30]. - The pharmaceutical industry is expected to continue growing due to factors such as aging population and consumption upgrades[29]. - The company aims to achieve low-cost operations through improved production efficiency and quality control, while implementing automation[99]. - The company will actively seek high-quality acquisition targets to enhance its core business and drive high-quality development[100].

证券代码：002900 证券简称：哈三联 公告编号：2020-071 哈尔滨三联药业股份有限公司 关于参加投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，哈尔滨三联药业股份有限公司（以下简 称"公司"）将参加由黑龙江省上市公司协会、深圳市全景网络有限公司共同举 办的"黑龙江省上市公司 2020 年度投资者网上集体接待日"活动，现将有关事 项公告如下： 本次集体接待日活动将通过深圳市全景网络有限公司提供的互联网平台举 行，投资者可以登录"全景•路演天下"网站（http://rs.p5w.net）参与公司本次 投资者集体接待日活动，时间为 2020 年 11 月 12 日（周四）14:00 至 16:30。 届时公司董事、副总经理兼董事会秘书赵庆福先生、副总经理兼财务总监韩 冰女士将通过网络在线问答互动的形式，与投资者就公司治理、发展经营情况和 可持续发展等投资者关注的问题进行交流。 欢迎广大投资者积极参与。 特此公告。 哈尔滨三联药业股份有限公司 董事会 2020 年 11 月 9 日 1 ...

Financial Performance - Operating revenue for the reporting period was CNY 339,293,038.86, down 32.77% year-on-year, and CNY 966,463,406.42 for the year-to-date, down 40.75%[7] - Net profit attributable to shareholders was a loss of CNY 5,950,895.85, a decrease of 117.61% year-on-year, and CNY 22,160,046.26 for the year-to-date, down 85.30%[7] - Basic earnings per share for the reporting period was -CNY 0.02, a decrease of 118.18% year-on-year, and CNY 0.07 for the year-to-date, down 85.42%[7] - Total revenue decreased by 40.75% to ¥966,463,406.42 compared to ¥1,631,127,186.84 in the same period last year, primarily due to the impact of COVID-19 on business operations and logistics[15] - The estimated cumulative net profit for the year is projected to be ¥26 million, a decrease of 85.05% compared to the previous year's ¥38 million[25] - Basic earnings per share are expected to be ¥0.08, down 85.96% from ¥0.12 in the same period last year[25] - The company reported a 76.93% decrease in income tax expenses to ¥11,150,518.35, correlating with the decline in total profit[16] - The company reported a net cash outflow from operating activities of ¥69,554,061.33, compared to a net inflow of ¥279,304,766.42 in the same period last year[61] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,468,487,161.09, a decrease of 7.62% compared to the end of the previous year[7] - Total liabilities decreased to ¥683.48 million from ¥820.44 million year-over-year[37] - The company's equity attributable to shareholders decreased to ¥1.77 billion from ¥1.83 billion at the end of 2019[38] - The company's total assets amounted to CNY 2,562,770,818.84, slightly down from CNY 2,594,310,195.91[41] - Total liabilities decreased to CNY 572,918,453.89 from CNY 636,666,439.76 year-on-year[41] - The company's total equity reached approximately $1.96 billion as of Q3 2020[75] - Short-term borrowings increased by 55.28% to ¥279,506,863.16 from ¥180,000,000.00, reflecting new bank loans during the reporting period[15] Cash Flow - The net cash flow from operating activities was CNY 25,123,503.26, down 84.89% compared to the same period last year[7] - The company generated ¥1,183,661,019.44 in cash inflows from operating activities, down 34.5% from ¥1,807,621,940.65 in the previous year[61] - The net cash flow from investing activities was ¥167,825,057.20, compared to a net outflow of ¥90,278,640.89 in the same period last year[62] - The company’s total operating cash inflow was 1,011,758,540.38 CNY, compared to 1,314,944,648.90 CNY in the previous period[63] - The net cash flow from investment activities was 199,719,056.76 CNY, a turnaround from -82,101,423.99 CNY in the previous period[65] Shareholder Information - The company reported a total of 20,999 common shareholders at the end of the reporting period[11] - The largest shareholder, Qin Jianfei, holds 39.07% of the shares, with a total of 123,705,000 shares, of which 36,110,000 are pledged[11] - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[12] - The company repurchased 6,815,183 shares, accounting for 2.1526% of total share capital, with a total transaction amount of ¥85,754,696.02[17] Government Support and Subsidies - The company received government subsidies amounting to CNY 71,341,708.00, primarily related to government support and deferred income amortization[8] - Other income rose by 118.49% to ¥70,903,473.13, driven by an increase in government subsidies received[15] Investment Projects - The company reported a total investment of RMB 74,783 million in the pharmaceutical production base construction project, with a cumulative input of RMB 24,515.49 million, achieving 32.78% of the planned progress as of September 2022[23] - The marketing and service network center project has a total investment of RMB 5,093.9 million, with an input of RMB 2,960.59 million, reaching 58.12% of the planned progress as of June 2021[23] - The total amount of funds raised for investment projects is RMB 90,011.9 million, with a cumulative input of RMB 27,527.56 million[23] - The pharmaceutical production base construction project is experiencing delays due to the impact of the COVID-19 pandemic and changes in market conditions[23] Research and Development - Research and development expenses for Q3 2020 were CNY 25,256,016.29, compared to CNY 20,540,569.60 in the previous year[44] - Research and development expenses increased to ¥80,481,766.68, up from ¥62,905,822.61, representing a growth of 28%[52] - The company is currently optimizing production lines and introducing innovative technologies to enhance production automation and capacity, aiming to improve market competitiveness[23] - The engineering technology research center project is in the concept design phase, with a focus on attracting top R&D talent and enhancing product development capabilities[23] Market Conditions and Strategy - The company is adjusting its marketing strategies and optimizing its sales service system in response to significant changes in national pharmaceutical policies[23] - The company anticipates a significant decline in operating revenue due to adjustments in the national key monitoring reasonable drug use catalog[26] - Fixed expenses, including asset depreciation, are expected to remain stable despite the revenue decline, while R&D expenses are projected to increase compared to the previous year[26]

哈尔滨三联药业股份有限公司 2020 年半年度报告全文 哈尔滨三联药业股份有限公司 2020 年半年度报告 2020-049 2020 年 08 月 1 哈尔滨三联药业股份有限公司 2020 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人秦剑飞、主管会计工作负责人韩冰及会计机构负责人(会计主管 人员)赵志成声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司可能面临新冠肺炎疫情影响的风险、行业政策变化风险、新药研发风 险、原材料价格波动及供应风险、药品招标降价的风险、募投项目实施的风险、 风险投资收益波动的风险等，详细内容已在本报告第四节"经营情况讨论与分 析（十）、公司面临的风险和应对措施"部分予以描述。敬请广大投资者注意投 资风险。 | | | | 第一节 重要提示、目录和释义 | 2 | | --- | --- | | 第二节 公司简介和主要财务指标 | 6 | | 第三节 公司业务概要 | ...

哈尔滨三联药业股份有限公司 2019 年年度报告全文 哈尔滨三联药业股份有限公司 2019 年年度报告 2020-019 2020 年 04 月 1 哈尔滨三联药业股份有限公司 2019 年年度报告全文 第一节重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人秦剑飞、主管会计工作负责人韩冰及会计机构负责人(会计主管 人员)赵志成声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司年度报告所涉及未来计划等前瞻性陈述不构成公司对投资者的实质承 诺，投资者及相关人士均应当对此保持足够的风险认识，并且应当理解计划、 预测与承诺之间的差异。 公司可能面临行业政策变化风险、新药研发风险、原材料价格波动及供应 风险、募投项目实施的风险、风险投资收益波动的风险、新冠肺炎疫情影响的 风险等，详细内容已在本报告第四节"经营情况讨论与分析（九）、公司面临的 风险"部分予以描述。敬请广大投资者注意投资风险。 公司经本次董事会审议通过的利润分配预案为：以利润 ...

哈尔滨三联药业股份有限公司 2019 年第三季度报告全文 哈尔滨三联药业股份有限公司 2019 年第三季度报告 2019 年 10 月 1 哈尔滨三联药业股份有限公司 2019 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人秦剑飞、主管会计工作负责人韩冰及会计机构负责人(会计主管 人员)赵志成声明：保证季度报告中财务报表的真实、准确、完整。 2 哈尔滨三联药业股份有限公司 2019 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 2,693,255,974.84 | | 2,513,555,386.13 | 7.15% | | 归属于上市公司股东的净资产（元） | 1,812, ...

哈尔滨三联药业股份有限公司 2019 年半年度报告全文 哈尔滨三联药业股份有限公司 2019 年半年度报告 2019-059 2019 年 08 月 1 哈尔滨三联药业股份有限公司 2019 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人秦剑飞、主管会计工作负责人韩冰及会计机构负责人(会计主管 人员)赵志成声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司可能面临行业政策变化风险、新药研发风险、原材料价格波动及供应 风险、药品招标降价的风险、募投项目实施的风险、风险投资收益波动的风险 等，详细内容已在本报告第四节"经营情况讨论与分析（十）、公司面临的风险 和应对措施"部分予以描述。 敬请广大投资者注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 重要提示、目录和释义 2 | | --- | | 第二节 公司简介和主要财务指标 6 | | 第三节 公司业务概要 ...